Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today’s newsletter has a bit of everything: peptides, China, Congress, and cancer drugs. Biotech in 2026 is never dull.
Hims and Noom take peptides further into mainstream
Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses. Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Source: www.statnews.com



